NCT06072833 2026-03-16
Characterizing and Addressing Financial Toxicity in AYAs With Cancer
Columbia University
Phase NA Completed
Clinical Trials
77 trialsNCT05993299 2026-03-11
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT03833167 2026-03-10
KEYNOTE-630
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04055948 2026-03-09
Building Family Caregiver Skills Using a Simulation-Based Intervention for Care of Cancer Patients
Case Comprehensive Cancer Center
Phase NA Completed
NCT04913259 2026-03-03
TS-PAC
Institut Bergonié
Phase NA Active not recruiting
NCT05148078 2026-03-02
Pediatric Radiation Oncology With Movie Induced Sedation Effect (PROMISE)
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT01602380 2026-02-27
FALCON
AstraZeneca
Phase 3 Completed
NCT03976362 2026-02-25
KEYLYNK-008
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05024968 2026-02-25
Sintilimab in Cancer of Unknown Primary
M.D. Anderson Cancer Center
Phase 2 Completed
NCT06837090 2026-02-20
SPAINTRK
Grupo Espanol de Tumores Neuroendocrinos
Completed
NCT04150900 2026-02-19
1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck
University of Maryland, Baltimore
Phase 2 Active not recruiting
NCT03388190 2026-02-13
METIMMOX
University Hospital, Akershus
Phase 2 Completed
NCT03260023 2026-02-05
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
Transgene
Phase 1/2 Active not recruiting
NCT03964727 2026-01-30
TROPiCS-03
Gilead Sciences
Phase 2 Active not recruiting
NCT04260529 2026-01-29
CICILIA
Cytovation AS
Phase 1/2 Completed
NCT03436290 2026-01-28
SCOPE
Vanderbilt University Medical Center
Phase NA Active not recruiting
NCT02952248 2026-01-27
A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT03697304 2026-01-27
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
Boehringer Ingelheim
Phase 2 Completed
NCT03824158 2026-01-14
Patient-centered and Efficacious Advance Care Planning in Cancer: the PEACe Comparative Effectiveness Trial
University of Pittsburgh
Phase NA Completed
NCT01968109 2026-01-06
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT06013176 2025-12-29
BEST-PRO
Abramson Cancer Center at Penn Medicine
Phase NA Completed
NCT03433898 2025-12-19
This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer
Boehringer Ingelheim
Phase EARLY_PHASE1 Completed
NCT02275910 2025-12-16
Phase 1 Study of E7090 in Subjects With Solid Tumor
Eisai Inc.
Phase 1 Completed
NCT03473652 2025-12-15
APPAHOCA
Centre Francois Baclesse
Phase NA Completed
NCT06347731 2025-12-15
Varian ProBeam360° Proton Therapy System China Clinical Trial (Wuhan)
Varian, a Siemens Healthineers Company
Phase NA Completed
NCT03676010 2025-12-10
DATECAN-1
Institut Bergonié
Active not recruiting
NCT04021043 2025-12-03
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT05383170 2025-11-28
Catalyst
Cytovation AS
Phase 1/2 Completed
NCT04266912 2025-11-25
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT04585269 2025-11-25
Bright IDEAS - Young Adults Problem-Solving Skills Training
Rutgers, The State University of New Jersey
Phase NA Active not recruiting
NCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
NCT03872427 2025-11-14
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05847686 2025-11-05
Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer
University of Washington
Phase 1/2 Completed
NCT03480646 2025-10-29
ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer
Constellation Pharmaceuticals
Phase 1/2 Completed
NCT05694013 2025-10-22
ORIGAMA
Hoffmann-La Roche
Phase 2/3 Terminated
NCT02959437 2025-10-21
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
Incyte Corporation
Phase 1/2 Terminated
NCT04197713 2025-10-20
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04010240 2025-10-16
NTRK
Institut Bergonié
Completed
NCT04639219 2025-10-16
DPT01
AstraZeneca
Phase 2 Active not recruiting
NCT03842228 2025-10-14
COD
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02874001 2025-10-06
PO-BADO
Institut Bergonié
Completed
NCT03963518 2025-10-06
SURROGATE-ICI
Institut Bergonié
Completed
NCT03972150 2025-10-06
A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT03676218 2025-10-03
DATECANelderly
Institut Bergonié
Completed
NCT03694171 2025-10-03
Access to Care and Prognosis in Elderly With Cancer (INCAPAC Study)
Institut Bergonié
Completed
NCT05407675 2025-10-03
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02674152 2025-10-01
Dose Finding Study of BI 836880 in Patients With Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT02689505 2025-10-01
Weekly BI 836880 in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT02079740 2025-09-30
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04614662 2025-09-23
Symptom Screening Linked to Care Pathways
The Hospital for Sick Children
Phase NA Completed